Congress of the European Crohn's and Colitis Organisation (ECCO)

Celltrion, Samsung Bioepis Unveil New Biosimilar Data in CD, UC at ECCO 2024

February 23rd 2024

Article

At the Congress of European Crohn’s and Colitis Organisation (ECCO), Celltrion and Samsung Bioepis presented new finding from their respective biosimilar analyses, demonstrating positive safety and efficacy measures for the biosimilars as treatments for Crohn disease (CD) and ulcerative colitis (UC).

Celltrion Publishes Data on Maintenance Therapy Using Infliximab Biobetter

March 6th 2023

Article

At the European Crohn’s and Colitis Organisation congress, Celltrion Healthcare shared positive safety and efficacy data on maintenance therapy including its infliximab biobetter allowing for subcutaneous administration, Remsima SC.

Investigators Elucidate ADA Predictive Value of Infliximab Clearance in Crohn Disease

July 26th 2021

Article

Concomitant use of immunomodulators and dosage are important variables in the development of antidrug antibodies (ADAs) for patients receiving infliximab for Crohn disease, investigators report.

Investigators Report Findings on Infliximab Switching in IBD

July 21st 2021

Article

Pharmacokinetic, safety, and efficacy findings for patients with inflammatory bowel disease (IBD) were presented at the European Crohn's and Colitis Organization's annual meeting.

Adalimumab Biosimilar Transition Studies Reported at ECCO'21 Congress

July 13th 2021

Article

Presentations at the European Crohn's and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data.

New Research Assesses Factors That May Impact Adalimumab Therapy in IBD

March 8th 2019

Article

During this week’s 14th Congress of the European Crohn’s and Colitis Organisation, multiple research teams reported on efforts to better understand the factors that impact adalimumab therapy in patients with inflammatory bowel disease (IBD).

2 New Studies Highlight Safety, Efficacy, PK of Subcutaneous CT-P13

March 7th 2019

Article

Celltrion, maker of biosimilar infliximab CT-P13 (Remsima, Inflectra), has recently submitted an application to the European Medicines Agency for a subcutaneous formulation of the biosimilar.

Investigators Present Data on ADA Development, TDM for Biosimilar Adalimumab

March 6th 2019

Article

The advent of biosimilar adalimumab in the European Union was among the most eagerly awaited events for biosimilar stakeholders in 2018. During this week’s European Crohn’s and Colitis Organisation’s 14th Congress, held in Copenhagen, Denmark, research teams are presenting findings concerning antidrug antibody (ADA) development related to adalimumab and therapeutic drug monitoring (TDM) of one of those adalimumab biosimilars: Amgen’s ABP 501, sold in the European Union as Amgevita.

Studies Investigate Drug Survival, Discontinuation of Biologics in IBD

March 5th 2019

Article

In patients with ulcerative colitis and Crohn disease, treatment with biologics is often effective, but adverse events or loss of response may lead to discontinuation. Several studies that will be presented at this week’s European Crohn’s and Colitis Organisation’s 14th Congress, held in Copenhagen, Denmark, sought to investigate factors related drug survival and discontinuation of biologic therapies for inflammatory bowel disease (IBD).

Researchers Present Findings on Switching to CT-P13 in IBD

March 4th 2019

Article

This week, the European Crohn’s and Colitis Organisation (ECCO) will hold its 14th Congress in Copenhagen, Denmark. During the meeting, which runs from March 6-9, experts will gather from around the globe to discuss significant medical research into the treatment of inflammatory bowel disease (IBD), and numerous researchers will present findings on real-world switches to biosimilar infliximab CT-P13 (Inflectra, Remsima).